Other Information
−Removed: | June 30, 2024, Form 10-Q
+Added: | September 30, 2024, Form 10-Q
Exhibit Description
4 unchanged sentences
Amendment to the Bylaws of the Company dated March 2, 2023 (incorporated by reference to Exhibit 3.2 to the Company’s Current Report on Form 8-K filed on March 21, 2023).
+Added: Extension of Master Loan Agreement between IGC Pharma, Inc.
+Added: and O-Bank, CO., LTD.
+Added: (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on August 2, 2024).
+Added: Share Purchase Agreement, dated September 25, 2024, between IGC Pharma, Inc.
+Added: and Moran Global Strategies, Inc.
+Added: (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on September 27, 2024).
Rule 13a-14(a) / 15d-14(a) Certification of Chief Executive Officer.
10 unchanged sentences
Furnished herewith.
−Removed: | June 30, 2024, Form 10-Q
+Added: †Certain schedules or similar attachments to this exhibit have been omitted in accordance with Item 601(a)(5) of Regulation S-K.
+Added: | September 30, 2024, Form 10-Q
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
IGC PHARMA, INC.
−Removed: August 7, 2024
+Added: November 12, 2024
/s/ Ram Mukunda
1 unchanged sentence
(Principal Executive Officer)
−Removed: August 7, 2024
+Added: November 12, 2024
/s/ Claudia Grimaldi
2 unchanged sentences
(Principal Financial Officer)
−Removed: | June 30, 2024, Form 10-Q
+Added: | September 30, 2024, Form 10-Q
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.